ALEPH-2 Stats & Data

Identity and mislabeling: ALEPH‑2 is extremely rare in circulation. Confirm identity with multi‑reagent testing and, ideally, laboratory drug checking (FTIR/GC‑MS) before ingesting; mis-sold DOx/NBOMe/2C‑x has been documented in the wild. Shulgin lists oral activity at approximately 4–8 mg with 8–16 h duration; due to steep, idiosyncratic dose–response, first assays should be conservative (≤2–3 mg) and no redosing for at least 3 h to avoid stacked overduration and overstimulation. Thio‑substituted phenethylamines (e.g., 2C‑T‑2/‑7) have a track record of unpredictable toxicity and wide interindividual sensitivity; avoid insufflation or parenteral routes because of local irritation and greater unpredictability. Cardiovascular load (tachycardia, vasoconstriction, BP elevation) and mydriasis/bruxism are common; those with cardiovascular, seizure, or significant psychiatric histories should avoid or use only with medical clearance. Potential weak reversible MAO‑A inhibition has been reported in vitro for para‑alkylthio amphetamines; combinations with MAOIs or potent serotonergics (e.g., MDMA, high‑dose tryptamines) increase the risk of hypertensive or serotonergic crises. Onset can be slow and deceptive; early redoses frequently overextend duration and intensity. Plan set/setting and recovery (quiet environment, light nutrition, electrolytes, and sleep hygiene) and anticipate insomnia late in the course; do not use alcohol to force sleep. If severe agitation, hyperthermia, chest pain, or continuous vomiting occur, seek urgent medical care and avoid taking additional substances to self‑treat. Because US mail‑in lab testing via DrugsData is on administrative pause (as of April 2025), consider local in‑person services listed via drugchecking community resources.